Skip to main content
Caplight Logo









Spear Bio

Spear Bio

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://spear.bio/

Last Round

Series A

Jul 29, 2024

Total Funding Raised

$45M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Spear Bio is a biotechnology company that develops ultrasensitive immunoassay technology for protein biomarker detection in research and clinical diagnostics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

immunoassayprotein biomarkerneurodegenerative diseasebiomarker detectionclinical diagnosticslaboratory automationprotein analysislife science toolsassay developmentCROclinical research organizationproteomicsbenchtop analyzerbiotech reagentsdrug discovery tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Spear Bio Comparables

Compare Spear Bio with similar companies based on industry and business-model similarity.

Spear Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alamar Biosciences
76%
Quantum Diamond Technologies Inc.
76%
Bio-Techne Corporation
74%

Spear Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 29, 2024
SeedNov 29, 2023

Key People

Founding team and executive leadership

Feng Xuan

Co-Founder & CEO

Founding Team

Zidong Wang

Chief Operating Officer

Executive Team

Spear Bio Investors

Notable investors and investment history

Spear Bio investors
InvestorRounds
CDH InvestmentsSeries A, Seed
Maverick VenturesSeed, Series A
Yonjin CapitalSeries A
Yonghua CapitalSeed
Foresite CapitalSeries A
CDH InvestmentsSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 46% MoM, from 4.1K to 6K.

  • Apr 9, 2026

    Presented at AD/PD 2026 and launched new neurodegenerative assays.

Spear Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Spear Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Spear Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range51
Year Founded2021
Last FundingJul 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?